In vitro studies have shown that inhibition of AURKA and Wnt/beta-catenin pathways can reduce the growth of adrenal cortical cancer cells, so targeting AURKA and beta-catenin may be a strategy to treat ACC (60). This evidence concerns the gene AURKA and adrenal cortex carcinoma.